MedPath

Nimotuzumab

Generic Name
Nimotuzumab
Drug Type
Biotech
CAS Number
780758-10-3
Unique Ingredient Identifier
6NS400BXKH
Indication

Investigated for use/treatment in head and neck cancer, brain cancer, pediatric indications, pancreatic cancer, lung cancer, and colorectal cancer.

Associated Conditions
Advanced Head and Neck Cancer, Advanced Stage Head and Neck Cancer, Glioblastoma Multiforme (GBM), High Grade Glioma (HGG), Advanced Epithelial Tumor of the Head and Neck
Clinical Trials
Related News

Immunotherapy of Advanced Cancer Using a Combination Nimotuzumab and NK Cells

Phase 1
Conditions
NK Cell Mediated Immunity
Advanced Cancer
ADCC
Adaptive Transfer
Nimotuzumab
Interventions
Biological: NK Cell adaptive transfer
First Posted Date
2018-06-13
Last Posted Date
2018-06-13
Lead Sponsor
Hangzhou Cancer Hospital
Target Recruit Count
21
Registration Number
NCT03554889
Locations
🇨🇳

Hangzhou Cancer Hospital, Hangzhou, Zhejiang, China

Study of Nimotuzumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer

Phase 2
Conditions
Stage III Cervical Cancer
Stage IVA Cervical Cancer
Cervical Adenosquamous Cell Carcinoma
Cervical Squamous Cell Carcinoma in Situ
Stage IB Cervical Cancer
Stage IIB Cervical Cancer
Neoplasms
Stage IIA Cervical Cancer
Interventions
Radiation: external-beam radiation
Radiation: brachytherapy
First Posted Date
2018-03-19
Last Posted Date
2018-08-13
Lead Sponsor
Zhujiang Hospital
Target Recruit Count
100
Registration Number
NCT03469531
Locations
🇨🇳

Zhujiang Hospital, Guangzhou, Guangdong, China

Study of Nimotuzumab and Irinotecan as Second Line With Recurrent or Metastatic Gastric Adenocarcinoma

Phase 2
Conditions
Stomach Neoplasms
Interventions
First Posted Date
2018-01-17
Last Posted Date
2018-01-17
Lead Sponsor
Peking University
Target Recruit Count
55
Registration Number
NCT03400592
Locations
🇨🇳

Peking cancer hospital, Beijing, Beijing, China

Radiation Plus Concurrent Nimotuzumab in Elderly Patients With Locoregionally Advanced Nasopharyngeal Carcinoma

Phase 2
Completed
Conditions
Nasopharyngeal Carcinoma
Interventions
Radiation: Radiation
First Posted Date
2017-01-20
Last Posted Date
2024-05-06
Lead Sponsor
Zhejiang Cancer Hospital
Target Recruit Count
30
Registration Number
NCT03025958
Locations
🇨🇳

Xiaozhong Chen, Hangzhou, Zhejiang, China

Nimotuzumab Plus S1 Versus Placebo Plus S1 as Maintenance Treatment in Patients With Unresectable Pancreatic Cancer

Phase 4
Conditions
Unresectable Pancreatic Cancer
Interventions
Drug: Placebo plus S1
First Posted Date
2016-10-26
Last Posted Date
2016-10-26
Lead Sponsor
Chinese PLA General Hospital
Target Recruit Count
60
Registration Number
NCT02945267
Locations
🇨🇳

Rocket Army General Hospital, PLA, Beijing, China

🇨🇳

Air Force General Hospital, PLA, Beijing, China

🇨🇳

The 306TH Hospital of PLA, Beijing, China

and more 4 locations

Simultaneous Integrated Boost Radiotherapy and Concurrent Nimotuzumab or Chemotherapy for Esophageal Carcinoma

Phase 2
Conditions
Esophageal Neoplasms
Interventions
Radiation: IMRT simultaneous integrated boost
Procedure: Esophagectomy
First Posted Date
2016-08-08
Last Posted Date
2019-07-26
Lead Sponsor
Chinese Academy of Medical Sciences
Target Recruit Count
120
Registration Number
NCT02858206
Locations
🇨🇳

Zefen Xiao, Beijing, Beijing, China

Phase II Clinical Trial of Concurrent Chemoradiotherapy Combined Nimotuzumab for Stage IIB-IVA Cervical Cancer

Phase 2
Conditions
Cervical Cancer
Interventions
Radiation: External Beam Radiation Therapy
Radiation: Internal Radiation Therapy
First Posted Date
2016-03-10
Last Posted Date
2016-03-10
Lead Sponsor
Air Force Military Medical University, China
Target Recruit Count
60
Registration Number
NCT02705612
Locations
🇨🇳

Department of Radiation Oncology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China

Nimotuzumab in Combination With Radio-chemotherapy for the Treatment of Brainstem Tumor in Children

Phase 2
Conditions
Childhood Brain Stem Neoplasm
Interventions
First Posted Date
2016-02-03
Last Posted Date
2018-10-16
Lead Sponsor
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Target Recruit Count
30
Registration Number
NCT02672241
Locations
🇨🇳

he Department of Radiation Oncology, Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China

Nimotuzumab in Combined With Paclitaxel and Cisplatin for Treatment of Metastatic Esophageal Squamous Cell Carcinoma

Phase 3
Conditions
Esophageal Squamous Cell Carcinomas
Interventions
Drug: Placebo
First Posted Date
2015-11-23
Last Posted Date
2016-02-01
Lead Sponsor
Biotech Pharmaceutical Co., Ltd.
Target Recruit Count
504
Registration Number
NCT02611700
Locations
🇨🇳

Chinese PLA General Hospital Medical School of Chinese PLA, Beijing, Beijing, China

🇨🇳

Cancer Hospital of Shantou University Medical College, Shantou, Guangdong, China

🇨🇳

AnHui Provincial Hospital, Hefei, Anhui, China

and more 24 locations

Nimotuzumab in Combination With Radiotherapy for Esophageal Cancer

Phase 2
Completed
Conditions
Esophageal
Interventions
Radiation: Radiotherapy
First Posted Date
2015-10-30
Last Posted Date
2022-03-17
Lead Sponsor
Biotech Pharmaceutical Co., Ltd.
Target Recruit Count
42
Registration Number
NCT02591784
Locations
🇨🇳

Wuhan Union Hospital, Wuhan, Hubei, China

🇨🇳

The Affiliated tumour hosiptal of HARBIN Medical University, Harbin, Heilongjiang, China

🇨🇳

Qilu Hospital,Shandong University, Jinan, Shandong, China

and more 2 locations
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy